CA

CanBas Co.,Ltd.

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.

4575 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CanBas Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on discovering and developing innovative oncology drugs, particularly in the field of immuno-oncology, that target the cell cycle. CanBas utilizes a proprietary screening system to advance its drug pipeline, which includes the clinical-stage candidate CBP501, a calmodulin-modulating peptide. A key objective of its research is to create anticancer treatments with fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:46
Regulatory News Service
確認書
Japanese 8.1 KB
2025-09-29 08:46
Annual Report
有価証券報告書-第26期(2024/07/01-2025/06/30)
Japanese 576.6 KB
2025-02-13 07:55
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-02-13 07:54
Interim Report
半期報告書-第26期(2024/07/01-2025/06/30)
Japanese 160.4 KB
2024-09-30 08:04
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-09-27 08:21
Governance Information
内部統制報告書-第25期(2023/07/01-2024/06/30)
Japanese 21.7 KB
2024-09-27 08:21
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:20
Annual Report
有価証券報告書-第25期(2023/07/01-2024/06/30)
Japanese 637.2 KB
2024-05-10 08:16
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-10 08:16
Quarterly Report
四半期報告書-第25期第3四半期(2024/01/01-2024/03/31)
Japanese 134.6 KB
2024-02-09 08:13
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-09 08:12
Interim Report
四半期報告書-第25期第2四半期(2023/10/01-2023/12/31)
Japanese 163.0 KB
2023-11-10 08:00
Regulatory News Service
確認書
Japanese 8.0 KB
2023-11-10 07:51
Quarterly Report
四半期報告書-第25期第1四半期(2023/07/01-2023/09/30)
Japanese 134.0 KB
2023-09-27 08:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea 378800
Shedir Pharma Group Logo
Develops and sells pharmaceutical, nutraceutical, and dermo-cosmetic products in Italy & Spain.
Italy SHE
SHIELD THERAPEUTICS PLC Logo
Commercializing a novel oral therapy for adults with iron deficiency.
United Kingdom STX
SHINPOONG PHARMACEUTICAL CO.,LTD Logo
R&D-driven pharma firm making APIs, finished drugs, and medical products for global markets.
South Korea 019170
Shionogi & Co.,Ltd. Logo
A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.
Japan 4507
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440

Talk to a Data Expert

Have a question? We'll get back to you promptly.